(Total Views: 679)
Posted On: 09/08/2020 11:15:32 PM
Post# of 154105
Daily report from BioPharm Catalyst on the drop of Moderna's SP today reads:
"Moderna, Inc. (NASDAQ:MRNA) shares closed down 13% to $54.34. Analysts at SVB Leerink cut their rating to underperform from market perform and reduced their price target to $41 from $58 on concerns about competition for a COVID-19 vaccine."
Has anyone heard of any advances from any of their vaccine competitors? I haven't despite seeing regular reports from MSM on the status of BP's leading contenders, so this has me wondering ... is the writer using vaccine as a generic term that is meant to include therapeutics that may point to the home team here?
"Moderna, Inc. (NASDAQ:MRNA) shares closed down 13% to $54.34. Analysts at SVB Leerink cut their rating to underperform from market perform and reduced their price target to $41 from $58 on concerns about competition for a COVID-19 vaccine."
Has anyone heard of any advances from any of their vaccine competitors? I haven't despite seeing regular reports from MSM on the status of BP's leading contenders, so this has me wondering ... is the writer using vaccine as a generic term that is meant to include therapeutics that may point to the home team here?
(0)
(0)
